Low-dose tocilizumab is associated with improved outcome and a low risk of secondary infection in severe COVID-19 pneumonia저용량 토실리주맙은 중증 COVID-19 폐렴에서 개선된 결과 및 낮은 2차 감염 위험과 관련이 있습니다Article Published on 2021-12-012022-09-12 Journal: International journal of clinical practice [Category] 진단, [키워드] age APACHE II score cause Clinical data clinical feature Comorbidity control group control patient Coronavirus disease 2019 COVID-19 Critical Cytokine storm death demographic died distinguishing dose Effect evaluated groups High-dose high-dose group hyper-inflammation IL-6 receptor Infection infection rate infiltration intravenously less low dose low-dose lower mortality lung damage mechanical ventilation Mortality mortality rate Non-invasive outcome Patient radiological receiving respiratory Retrospective study risk Risk factors Secondary infection Severe COVID-19 pneumonia severe pneumonia survived Symptom Tocilizumab tocilizumab administration treated two group [DOI] 10.1111/ijcp.14997 PMC 바로가기 [Article Type] Article
Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemicResearch article Published on 2021-12-012022-10-05 Journal: International Journal of Infectious Diseases [Category] SARS, 신약개발, 치료법, [키워드] Affect anticipated clinical trials Combination COVID-19 COVID-19 pandemic diagnosed diagnostic diagnostics drug Drug discovery drug regimens drug resistance drugs estimate Follow-up Health Service highlight Impact implementation Investing lower mortality MDR-TB multi-drug resistant National New drugs New treatment regimens Patient Pipeline positive regimen report Repurposed drug required tolerable Treatment Treatment outcome treatment regimen Tuberculosis WHO WHO guideline [DOI] 10.1016/j.ijid.2021.02.067 [Article Type] Research article
Kinetics of antibody response in critically ill patients with Middle East respiratory syndrome and association with mortality and viral clearanceArticle Published on 2021-11-192022-10-29 Journal: Scientific Reports [Category] COVID-19, MERS, [키워드] 95% CI Admission admitted to ICU antibody Antibody Response Antigen assessment association blood sample clearance coated with collected Corticosteroids Critically ill Critically ill patient Diseases ELISA enzyme-linked immunosorbent failure faster ICU IgG antibody immunology Immunotherapy implication invasive ventilation Kinetics lower mortality median MERS MERS patient MERS-CoV MERS-CoV RNA MERS-CoV S1 Middle East Mortality onset of symptom optical Pathogenesis Patient renal replacement therapy rRT-PCR significantly increased Signs and symptoms SOFA study cohort syndrome vasopressors viral clearance [DOI] 10.1038/s41598-021-01083-y PMC 바로가기 [Article Type] Article
Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19COVID-19 환자에서 입원 전 증상 기간에 따른 렘데시비르의 영향Article Published on 2021-11-122022-09-11 Journal: Journal of Antimicrobial Chemotherapy [Category] SARS, 치료제, [키워드] 95% CI Admission age analysed Analysis antiviral therapy benefit death demonstrated duration of symptoms evaluate higher risk hospital ICU identify Impact increase in Infection Invasive mechanical ventilation IQR lower mortality male median Mortality mortality rate multivariate analyses Multivariate analysis Patient patients with COVID-19 performed Pre-admission predictor Primary outcome receiving reduce reduced reduction in Remdesivir required SARS-CoV-2 Standard-of-care subgroup of patient survival symptom duration symptom onset Time to recovery Treatment [DOI] 10.1093/jac/dkab321 PMC 바로가기 [Article Type] Article
Disparities in COVID-19 Outcomes by Race, Ethnicity, and Socioeconomic Status A Systematic-Review and Meta-analysisResearch Published on 2021-11-112022-10-29 Journal: JAMA Network Open [Category] COVID-19, MERS, [키워드] 95% CI adjusted Admission affected African American age Alaska analyses Asian association clinical care COVID-19 criteria database Decreased Deprivation determinant determinants disease severity disparity Ethnicity evaluate extraction finding group groups higher risk highest Hispanic ICU admission Importance incidence independent individual individuals intensive care item less lower mortality measure Meta-analysis Mortality mortality rate Native objective Odds ratio outcome outcomes Patient Point populations positive positively correlated Prevalence public health quality score race Racial random-effects model Relevance reported Reporting Result review risk risk ratio RRs screened Selection Source status synthesis systematic review the United State was performed were assessed were excluded white with COVID-19 World Health Organization [DOI] 10.1001/jamanetworkopen.2021.34147 PMC 바로가기 [Article Type] Research
Decreased mortality and increased side effects in COVID-19 patients treated with IL-6 receptor antagonists: systematic review and meta-analysisIL-6 수용체 길항제로 치료받은 COVID-19 환자의 사망률 감소 및 부작용 증가 : 체계적인 검토 및 메타 분석Meta-Analysis Published on 2021-11-022022-09-01 Journal: Scientific Reports [Category] MERS, SARS, 임상, 진단, 치료법, [키워드] 1.26 antagonist antagonists baseline Cochrane Library COVID-19 COVID-19 patient COVID-19 patients database Decreased effective Epidemiology ICU IL-6 IL-6 receptor Immunotherapy impaired liver function Infectious diseases lower mortality mechanical ventilation Meta-analysis Mortality mortality risk neutropenia Patient patients hospitalized patients treated PMC PubMed Central random effect RCT receptor reducing mortality Research retrieved risk risk difference risk ratio Secondary infection secondary infections Side effect Side effects systematic review treated treating COVID-19 patients unique viral infection WHO [DOI] 10.1038/s41598-021-00726-4 PMC 바로가기 [Article Type] Meta-Analysis
Can treatment with teicoplanin improve the prognosis of COVID-19 patients?Clinical Trial Published on 2021-11-012022-10-05 Journal: International journal of clinical practice [Category] SARS, 임상, [키워드] addition administration Adverse reaction Arm baseline characteristics Can clinical investigation Clinical outcome Comorbidity comparable control arm control group COVID-19 COVID-19 patients effect of treatment hospitalised patient IMPROVE laboratory-confirmed lower mortality mortality rate mortality rate; no significant difference organization outcome Patient patients with COVID-19 presenting symptoms Prognosis reported required Retrospective study significantly significantly lower standard care Teicoplanin teicoplanin. treated Treatment two groups with COVID-19 [DOI] 10.1111/ijcp.14752 PMC 바로가기 [Article Type] Clinical Trial
Tocilizumab administration for the treatment of hospitalized patients with COVID-19: A systematic review and meta-analysis코로나19 입원환자 치료를 위한 토실리주맙 투여: 체계적 고찰 및 메타분석Review Published on 2021-11-012022-09-12 Journal: Respirology (Carlton, Vic.) [Category] MERS, SARS, 진단, [키워드] 95% CI administration Admission benefit clinically composite endpoint coronavirus coronavirus disease Corticosteroids COVID-19 Cytokine storm Effectiveness Efficacy evaluate Hospitalization hospitalized COVID-19 patients hospitalized patient ICU improved mortality IMV intensive care Invasive mechanical ventilation lower mortality management Meta-analysis Mortality nine non-ICU patient non-ICU patients observational studies observational study outcome Patient patients Randomized controlled trial RCT RCTs receiving reduction reduction in risk SARS-CoV-2 searched Secondary objective subgroup systematic review systemic corticosteroids Tocilizumab Treatment was reduced [DOI] 10.1111/resp.14152 PMC 바로가기 [Article Type] Review
Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: A retrospective cohort studyResearch Article Published on 2021-10-262022-10-28 Journal: PLoS ONE [Category] COVID-19, [키워드] 95% CI 95% confidence interval adjusted hazard ratio adjusted odds ratio administration Admission Clinical improvement Clinical outcome Cohort COVID-19 COVID-19 patient defined discharge early administration Hospital stay Hospitalized hospitalized patient ICU intensive care investigated less lower mortality mechanical ventilation medication Mortality objective outcome Patient patients hospitalized Primary outcome proportion receive Remdesivir reported Result retrospective cohort study secondary outcome symptom onset the timing treated Treatment with COVID-19 [DOI] 10.1371/journal.pone.0258643 PMC 바로가기 [Article Type] Research Article
COVID-19 in children: an approach for multisystem inflammatory syndromeReview Published on 2021-10-262022-10-31 Journal: Egyptian Pediatric Association Gazette [Category] COVID-19, [키워드] acute respiratory syndrome Adults approach article cause characterized children clinical evidence clinical feature coronavirus coronavirus disease Coronavirus-2 Corticosteroids COVID-19 COVID-19 patients database diagnosed Diagnosis elevated exaggerated immune response exclusion Fever gastrointestinal involvement Hyperinflammatory Hyperinflammatory syndrome immunoglobulins Infection Inflammatory inflammatory markers information Intravenous immunoglobulin IVIG Kawasaki lack lower mortality management mechanism Mild symptom MIS-C multiorgan failure Multisystem inflammatory syndrome Organ failure pathophysiologic pathophysiology pediatric pediatrics Rash retrieved SARS-CoV-2 SARS-COV-2 infection searched Specific subsequent syndrome Tocilizumab Topic treated Trial [DOI] 10.1186/s43054-021-00082-y PMC 바로가기 [Article Type] Review